Breast Carcinoma With Amplified HER2: A Gene Expression Signature Specific for Trastuzumab Resistance and Poor Prognosis

Modern Pathology - United Kingdom
doi 10.1038/modpathol.2010.125
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Src, a Potential Target for Overcoming Trastuzumab Resistance in HER2-positive Breast Carcinoma

British Journal of Cancer
Cancer ResearchOncology
2014English

Resistance to Trastuzumab in HER2-Positive Mucinous Invasive Ductal Breast Carcinoma

Clinical Breast Cancer
Cancer ResearchOncology
2013English

Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It

Clinical Medicine Insights: Oncology
Oncology
2016English

Cytokeratin 5/6 Fingerprinting in HER2-positive Tumors Identifies a Poor Prognosis and Trastuzumab-Resistant Basal-Her2 Subtype of Breast Cancer

Oncotarget
Oncology
2015English

ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer

Frontiers in Oncology
Cancer ResearchOncology
2019English

Sixteen-Kinase Gene Expression Identifies Luminal Breast Cancers With Poor Prognosis

Cancer Research
Cancer ResearchOncology
2008English

Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Gene Expression Profiling of Carcinoma Breast and Its, Prognostic Signature: A Review

Academia Journal of Surgery
2019English

Flotillin2 Expression Correlates With HER2 Levels and Poor Prognosis in Gastric Cancer

PLoS ONE
Multidisciplinary
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy